Is the currently available data from INAVO sufficient to adopt this as a new standard of care for all patients or are you awaiting overall survival and/or PROs?  

The results of the INAVO120 trial are sufficient to be practice changing for patients who meet the study eligibility criteria. The improvement in progression-free survival was nearly an 8-month improvement. Although the control arm included palbociclib, which has not shown overall survival benefits ...

The difference in the progression-free survival was quite significant (15 months compared to 7.3 without inavolisib), and there is an overall survival benefit as well for this regimen. This should be considered the standard of care for patients appropriate for triplet therapy.

The INAVO120 trial has published that inavolisib, a selective PI3Kα inhibitor, in combination with palbociclib and fulvestrant, significantly improved progression-free survival (PFS) in patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.&n...

The phase 3 INAVO120 trial was a prospective, double-blind, randomized effort to compare the fulvestrant/palbociclib doublet with a triplet regimen including the novel PI3K inhibitor inavolisib. This study addressed an important unmet clinical need in the subgroup of patients who have demonstrated r...